Background: Two methods for testing inducibility of atrial fibrillation (AF)-atrial
| INTRODUCTION
Although pulmonary vein isolation (PVI) is a well-established treatment for paroxysmal atrial fibrillation (AF), this strategy has been reported to be insufficient for treating persistent AF, with suboptimal success rate. 1 This led to the development of the adjunctive ablation strategies to target nonpulmonary vein (PV) triggers 2, 3 and atrial substrate for perpetuating AF, including ablation of complex fractionated atrial electrograms (CFAE) 4 and linear lesion creation in the left atrium (LA). 5, 6 However, it remains unclear how to select patients requiring each adjunctive ablation strategy beyond PVI.
Two different methods, rapid atrial pacing [7] [8] [9] [10] [11] [12] and high-dose isoproterenol infusion, 13, 14 have been proposed to test the inducibility of atrial tachyarrhythmia to determine the endpoint of catheter ablation after PVI. These alternate methods for testing inducibility may evaluate separate mechanisms for the development of AF. While rapid atrial pacing may test the arrhythmogenic substrate, isoproterenol may be useful to provoke potential non-PV triggers of AF. Previous studies showed that noninducibility with each method was useful to evaluate the prognostic value after AF ablation in paroxysmal AF. [7] [8] [9] [10] [11] [12] [13] [14] However, the clinical role of a combination of the dual inducibility method at the end of the ablation procedure is still unclear. This study was performed to assess the incidence of atrial tachyarrhythmia inducibility with the dual methods following PVI and the impact of each electrophysiological and pharmacological inducibility on the long-term outcome in patients with paroxysmal and persistent AF.
| ME TH ODS

| Subjects
A total of 297 consecutive patients undergoing initial catheter ablation for drug-refractory AF between October 2011 and February 2014 in the Cardiovascular Institute were identified. Paroxysmal AF was defined as AF that self-terminated in 7 days or less, while persistent AF was defined as continuous AF that lasted for more than 7 days. After excluding six patients for whom inducibility of atrial tachyarrhythmia was not sequentially assessed with the dual methods, 291 patients were included in the analysis. All patients provided written informed consent prior to the procedure, and the Institutional Review Board of the Cardiovascular Institute approved the study (Date of IRB approval; January 28, 2016; Approval number, 285).
| Procedural details
All patients had anticoagulation therapy for more than 3 weeks before ablation and underwent transesophageal echocardiography to exclude atrial thrombus within 3 days before ablation. Oral anticoagulant drugs except warfarin were interpreted on the morning of the procedure. All antiarrhythmic drugs (AAD) were discontinued for at least five half-lives, and no patients received any oral amiodarone therapy before the procedure. All procedures were performed under deep sedation using fentanyl and continuous infusion of propofol. A temperature probe (Sensitherm; St. Jude Medical, St. Paul, MN) was placed at the mid-portion of the esophagus through the nose, and esophageal temperature was monitored continuously during the pro- Halo catheter was placed along the tricuspid annulus to assess the bidirectional conduction block using a differential pacing method. Figure 1 shows the procedural flowchart in this study. After completion of PVI and CTI ablation, the inducibility of atrial tachyarrhythmia was assessed sequentially with two methods. First, electrophysiological inducibility (EPI) was assessed by rapid atrial pacing, which was delivered from proximal CS for 5 seconds, starting at a pacing cycle length of 250 ms, and reducing in steps of 10 ms to a minimum of 180 ms at 3 seconds intervals, without administration of isoproterenol. Positive EPI was defined as sustained AF/AT for at least 
| Inducibility tests and adjunctive ablation strategy
| Follow-up
All patients were followed up at our outpatient clinic every month for 3 months after the procedure and thereafter every 2-3 months for 9 months after the procedure. Oral anticoagulants were maintained for at least 3 months after the procedure. AAD except beta-blockers were continued for 1-2 months and then discontinued if the patients had no AF/AT recurrence. AF/AT recurrence was defined as any episode of atrial tachyarrhythmia lasting >30 seconds after 3 months of the blanking period without AAD. 
| RESULTS
| Patient characteristics
The baseline characteristics of the patients are summarized in 
| Results of inducibility tests and ablation procedures
PVI and CTI ablation were performed successfully in all patients.
After PVI, sustained AF was terminated by DCCV in 113 patients:
19 of 188 (10.1%) paroxysmal AF patients and 94 of 103 (91.2%) persistent AF patients. The results of inducibility tests and procedural results are summarized in Table 2 . EPI and PHI were observed in 55 (18.9%) and 75 (25.8%) of 291 patients, respectively. The incidence of EPI was significantly higher in patients with persistent AF than paroxysmal AF (32.0% vs 11.7%, respectively, P < .001). There was no significant difference in the incidence of PHI between paroxysmal and persistent AF (26.1% vs 25.2%, respectively, P = .87). 
| Follow-up
During a mean follow-up period of 42.5 AE 9. 
| Clinical Impact of neither electrophysiological nor pharmacological inducibility
The 291 patients were reassessed and divided into two groups After the single ablation procedure, although there were no significant differences in AF/AT recurrence-free rate between Group 1 and Group 2 in paroxysmal AF (71.2% vs 73.0%, respectively, logrank test, P = .751; Figure 2C ), in the persistent AF, Group 1 had a significantly higher AF/AT recurrence-free rate than Group 2 (68.5% vs 49.0%, respectively, log-rank test, P = .022; Figure 2D ). 
| Complications
One case of pericardial effusion requiring pericardiocentesis seen after the ablation procedure occurred in Group 2 of persistent AF.
There were no cases of symptomatic stroke, symptomatic PV stenosis, or atrioesophageal fistula in this study.
| DISCUSSION
| Main findings
The present study was performed to examine the impacts of electro- 
| Electrophysiological and pharmacological inducibility
In the present study, the electrophysiological test was performed to assess atrial vulnerability from rapid atrial stimulation and sustainability for perpetuating AF, and the pharmacological test was used to provoke residual focal source for initiating AF following PVI.
A number of studies have suggested that noninducibility of AF by atrial pacing at the end of AF ablation is associated with lower rates of F I G U R E 2 Kaplan-Meier estimate curve comparing freedom from AF/AT recurrence according to the results of inducibility tests after a single procedure. A, Paroxysmal AF. B, Persistent AF. C, Paroxysmal AF. D, Persistent AF. AF, atrial fibrillation; AT, atrial tachycardia; EPI, electrophysiological inducibility; PHI, pharmacological inducibility; Group 1, neither electrophysiological inducibility nor pharmacological inducibility after pulmonary vein isolation; Group 2, either electrophysiological inducibility or pharmacological inducibility, or both after pulmonary vein isolation AF recurrence, especially in patients with paroxysmal AF. [7] [8] [9] [10] 12 The incidence of pacing-induced AF following PVI in the present study was lower than in previous studies (28.2%-60.0% in paroxysmal [7] [8] [9] [10] [11] [12] [14] [15] [16] [17] and 42%-62% in persistent AF 9, 11, 16, 17 ). In addition, the present study showed no significant association between electrophysiological inducibility and long-term outcome in patients with paroxysmal or persistent AF. Consistent with our findings, previous studies have indicated no prognostic value in pacing-induced AF following PVI. 11, [15] [16] [17] These differences in the prognostic significance of electrophysiological inducibility may be related to (i) the pacing protocol, (ii) the definition of inducible AF, and (iii) the ablation strategy. Our pacing protocol was based on previous studies evaluating the incidence of pacing-induced AF in patients without clinical AF to decrease the number of nonspecific AF inductions. 18, 19 Therefore, our pacing protocol was less aggressive than those used in previous studies evaluating inducibility of AF after ablation. [7] [8] [9] [10] [11] [12] 14, 15 Second, the definition of inducibility of AF also differed widely in the minimum duration of induced AF considered to be significant (10 seconds 9 up to 10 minutes 10, 15 ). In the present study, positive electrophysiological inducibility was considered as sustained AF lasting >5 minutes, because a short duration (<5 minutes) of inducible AF was suggested to be a nonspecific phenomenon in clinical practice. 11, 19 Moreover, shorter duration of AF is also not suitable for mapping to identify the AF substrate including the location of CFAE or reentrant circuits.
Finally, the ablation strategy for adjunctive ablation lesions following inducibility test was heterogeneous among previous studies. [7] [8] [9] [10] [11] [12] 14, 15 In the present study, limited CFAE ablation without empirical linear ablation lesions in LA was performed as substrate modification
Comparison of cumulative freedom from AT/AF recurrence according to the results of inducibility tests using the logrank test between paroxysmal and persistent AF. AF, atrial fibrillation; AT, atrial tachycardia; EPI, electrophysiological inducibility; PHI, pharmacological inducibility AF = atrial fibrillation; CHADS2 = congestive heart failure, age over 75 years, diabetes mellitus, previous stroke/transit ischemic attack; CHA2DS2VASc = congestive heart failure, age over 75 years old, diabetes mellitus, previous stroke/transit ischemic attack, vascular disease, age 65-74 years, sex; LA = left atrium; LVEF = left ventricular ejection fraction; NA = not applicable.
Values are expressed as mean AE SD or as n (%).
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for pacing-induced AF, and the incidence of persistent AT following the initial ablation procedure was low (6.5%) in patients with persistent AF. Consistent with our findings, a previous study suggested that a limited CFAE ablation strategy provides a lower incidence of recurrent macroreentrant AT, and better reverse remodeling of the LA compared with extensive CFAE ablation strategies in the initial ablation procedure for persistent AF. 20 Further selective approach for substrate modification is necessary to improve clinical for pacinginduced AF.
Isoproterenol is most commonly used to provoke non-PV triggers in patients without spontaneously firing non-PV triggers. 13, 14 Using our protocol, non-PV triggers inducing AF could be induced in 1.0% of cases, which was lower than in previous studies (11%-32% 14, [21] [22] [23] ).
However, the incidence of non-PV foci including non-PV ectopic beats not initiating AF was comparable. 21 The difference in rate of pharmacological inducibility of AF may have been related to our protocol of isoproterenol infusion, that is, lower total dosage and shorter infusion time, 13, 14 and lack of DCCV of pacing-induced AF during isoproterenol infusion 24 compared with previous studies. In addition, CFAE ablation may have resulted in fortuitous ablation of non-PV foci, because the sites of the origin of the non-PV triggers were found to be associated with the location of those of the presence of CFAE. 25, 26 Many investigators have reported that non-PV triggers inducing AF are associated with higher AF recurrence rate, 14, 22, [27] [28] [29] [30] [31] and ablation of non-PV triggers added to PVI has been shown to improve the clinical outcome in patients with paroxysmal AF. 28, 30, 31 In addition, Elayi et al 26 reported that non-PV ectopic beats not inducing AF were also associated with higher AF recurrence rate. Thus, our approach for ablation strategy of non-PV foci may contribute to prevention of long-term outcomes in patients with paroxysmal AF. reported that unsuccessful identification of non-PV triggers is significantly associated with AF recurrence. 27, 28 In addition, the recurrence of non-PV foci was even found in 30% of patients successfully eliminating these triggers. 22 Therefore, further studies are necessary to determine the optimal methods for provoking AF triggers and mapping the accurate localization of non-PV/SVC foci, and an optimal endpoint of ablation for non-PV/SVC foci. AF = atrial fibrillation; AT, atrial tachycardia; CHADS2 = congestive heart failure, age over 75 years, diabetes mellitus, previous stroke/transit ischemic attack; EPI = electrophysiological inducibility; LA = left atrium; PHI = pharmacological inducibility. Consistent with our findings, the recent meta-analysis of the PVI-only strategy in persistent AF patients showed a single-procedure arrhythmia-free survival rate of 66.7%. 32 A limited ablation strategy of PVI and ablation of only documented non-PV triggers was also found to provide transformation from persistent to paroxysmal AF, 33 and good long-term AF control with a low frequency of AT in the majority of patients. 34 Our data also indicated that patients with more enlarged LA diameter and with diabetes mellitus were more likely to have inducible atrial tachyarrhythmias in persistent AF. These factors were associated with progressive remodeling to maintain perpetuating AF with intraatrial conduction delay and decreased voltage. 35, 36 Ablation strategies for persistent AF have not been well established. Our observations suggest that the combination of electrophysiological and pharmacological inducibility tests at the end of the ablation procedure may be effective for evaluating alternate mechanisms of non-PV substrate or non-PV triggers and could determine the optimal endpoint of the ablation procedure in individual patients.
However, further selective approaches are required to improve the outcome of inducible atrial tachyarrhythmia following PVI in patients with persistent AF.
| Study limitations
The present study had several limitations. First, this was a prospective observational study, and the results of inducibility of atrial tachyarrhythmia were used to guide further ablation added to PVI.
In the present study, inducible atrial tachyarrhythmia was always targeted for ablation, and therefore, the clinical outcome might be modified by the additional ablation in patients with inducible atrial tachyarrhythmia following PVI.
Second, any substrate mapping to identify the localization of CFAE or low-voltage zone was not performed in the present study, and which might be useful to determine selective approaches for substrate modification in individual patients.
Finally, findings of repeat ablation procedures in patients with AT/AF recurrence could not be shown in the present study, because repeat ablation procedures were not fully performed in all patients with recurrent AF/AT. Although we did not assess AF burden after ablation, rare and/or shorter episodes of AF recurrence may be satisfactory to the patients or their physicians, and they may hesitate to refer for repeat ablation.
| CONCLUSION S
Achieving neither electrophysiological nor pharmacological inducibility of atrial tachyarrhythmia following PVI was associated with favorable long-term outcome in patients with persistent AF.
The combination of electrophysiological and pharmacological tests may discriminate patients likely to respond to a PVI-only strategy for persistent AF, with reduction of procedure time and unnecessary additional ablation lesions. Further studies are necessary to determine the optimal ablation strategy for induced atrial tachyarrhythmia after PVI, especially in patients with persistent AF.
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